ATLANTA -- Alan Weinstein, founder and former president of Premier, Inc., a group purchasing organization, has been named to the board of directors of Inviro Medical Devices, a manufacturer of infection control products. During his 30-year healthcare career, Weinstein focused on developing startup businesses that provide services to hospitals through shared programs intended to achieve greater economies of scale.
As a board member, Weinstein will provide strategic guidance to Inviro Medical Devices. I look forward to supporting this seasoned management team and offering insights gleamed from my years of working with GPO organizations and large hospital systems, says Weinstein. Impressive contracts with Premier and MedAssets have already been secured, and I plan to continue cultivating future opportunities on behalf of Inviro.
Weinstein retired from Premier in 2000 and currently consults with early- and growth-stage companies, providing sales and marketing guidance about how to approach and supply hospital systems and GPO organizations. He also serves on the board of directors of the American International Health Alliance and on the Robert Wood Johnson Foundation Advisory Committee for the Executive Nurse Fellows Program.
Attracting an industry leader, such as Alan Weinstein, to our board is another noteworthy accomplishment for this company, says Gareth Clarke, chief executive officer of Inviro Medical Devices. His stature and experience will benefit our management team, as well as have a positive impact on our product line, which now helps address both employee and patient safety. Weinsteins appointment, together with the recent board additions of Fred Brown, Todd Patrick and Tony Holler demonstrate Inviros ability to attract a world-class board of directors.
Source: Inviro Medical Devices
Â
Â
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.